Summary P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules.
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 15 molecules. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 3 and 5 respectively. Report covers products from therapy areas Central Nervous System, Oncology, Immunology, Genetic Disorders and Gastrointestinal which include indications Epilepsy, Inflammation, Neuropathic Pain (Neuralgia), Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Colorectal Cancer, Depression, Lung Cancer, Multiple Sclerosis, Prostate Cancer, Alzheimer’s Disease, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Duchenne Muscular Dystrophy, Hematological Tumor, Inflammatory Bowel Disease, Major Depressive Disorder, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Neuroinflammation, Pain and Solid Tumor.
The latest report P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2019, outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects - The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics
Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The market studied is expected to witness a rapid growth rate in the future, owing to factors, such as the rising prevalence of multiple sclerosis (MS) and the growing focus of companies on pipeline products for MS. - Big pharmaceutical companies have been investing heavily in the drug development process and are planning to target...
Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Inborn Gene or Chromosome Alterations...
Fabry Disease - Global Clinical Trials Review, H2 2020 Summary clinical trial report, “Fabry Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Fabry Disease Clinical trials scenario.This report provides top line data relating to the clinical trials on Fabry Disease. Report...
Lennox-Gastaut Syndrome Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H2, 2020" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario.This report provides top line data relating to the clinical trials...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.